Lifeboat Foundation

CHANTILLY, Va., Sept. 13, 2016 /PRNewswire/ — Vencore Labs Inc., a wholly owned subsidiary of Vencore Inc., announced today that it has been awarded two prime contracts for the Rapid Attack Detection, Isolation and Characterization Systems (RADICS) program led by the U.S. Defense Advanced Research Projects Agency (DARPA). The contracts have a total value of $17M and work is slated to begin in August of this year.

The objective of the RADICS program is to develop technologies for detecting and responding to cyberattacks on critical U.S. infrastructure, with an ultimate goal of enabling cyber and power engineers to restore electrical service within seven days in the event of a major attack. Vencore Labs, a leader in smart grid security and monitoring, will conduct research and deliver technologies in three of five technical areas (TA).

Can you say under statement with China’s new Radar.

The old countermeasures just aren’t cutting it anymore.

Luv this.

Researchers believe they can control the microscopic ‘fish’ to deliver drugs inside humans where they’re needed.

In early 2016 University Professor of Applied Physics Stephen Arnold earned a patent for his system for finding the size of one or more individual particles (such as nanoparticles) in real time using a microsphere’s whispering gallery modes.

Arnold and his team at Tandon’s MicroParticle PhotoPhysics Laboratory for BioPhotonics (MP3L) had generated excitement throughout the scientific community in 2012, when they created an ultra-sensitive biosensor capable of identifying the smallest single virus particles in solution.

Their technique was a major advance in a series of experiments to devise a diagnostic method sensitive enough to detect and a single virus particle in a doctor’s office or field clinic, without the need for special assay preparations or conditions. Normally, such assessment required the virus to be measured in the vacuum environment of an electron microscope, which added time, complexity and considerable cost.

Continue reading “Whispering gallery-mode biosensors are worth shouting about” »

The company will launch 200 miniature satellites through Virgin’s LauncherOne in order to provide mobile coverage to those living in remote areas worldwide.

Mechanically stacked two-dimensional Van-der-Waals heterostructures have been engineered to devise Terahertz frequency nano-detectors by using a flake of black phosphorus (BP) trapped between two layers of hexagonal boron nitride (hBN).

An international collaboration between researchers from Italy, USA, France and Poland brought together the benefits of heterostructure architecture and the potential of 2D layered nanomaterials to build THz photon sensors that operate over the 0.3−0.65 THz range, at low temperatures, with excellent signal to noise ratio values. They accomplished this by reassembling the thin isolated atomic planes of hexagonal borum nitride (hBN) with a few layer phosphorene (black phosphorus (BP)) in mechanically stacked hBN/BP/hBN heterostructures.

Artificial semiconductor heterostructures have an important role in modern electronic and photonic technologies, due to their effectiveness for manipulation and control of carriers from the visible to the THz range. Even though they are incredibly versatile, they usually require challenging production procedures due to the need of clean and abrupt interfaces. These characteristics are a major challenge for having high-efficiency devices at room temperature like source, detectors or modulators, especially in the far-infrared. With the emergence of two-dimensional (2D) layered materials, like graphene and phosphorene, as reliable, flexible and versatile alternatives for detectors operating at THz with low signal to noise ratio, this challenge was finally overcome.

Now, if we could just get the US to launch our own Quantum Satellite in space.

Recent research has taken quantum entanglement out of the theoretical realm of physics, and placed into the one of verified phenomena. An experiment devised by the Griffith University’s Centre for Quantum Dynamics, led by Professor Howard Wiseman and his team of researchers at the university of Tokyo, recently published a paper in the journal Nature Communications confirming what Einstein did not believe to be real: the non-local collapse of a particle’s wave function. (source)(source), and this is just one example of many.

Continue reading “Quantum Entanglement & Space Travel” »

A good summary article about the MitoSENS AMA on Reddit Futurology yesterday.

Aubrey de Grey, who should need little introduction here, is cofounder of the SENS Research Foundation, while Matthew O’Connor leads the foundation’s in-house research efforts. O’Connor’s focus is on the allotopic expression of mitochondrial genes, the complicated form of gene therapy needed to copy versions of these genes from the vulnerable mitochondrial genome into the much more secure nuclear genome, but altered in such a way that the resulting proteins can find their way back to the mitochondria where they are needed. Earlier today de Grey and O’Connor stopped by /r/futurology at Reddit to answer questions on this and other SENS rejuvenation research initiatives. One of the many benefits brought by this modern age of near zero cost communication is the way in which the barrier between researchers, supporters, and the public at large has faded to the point of non-existence. Any interested party can in a few minutes find out who is working in any specific areas of interest and reach out with questions or offers of support. Any researcher can find out where the interested parties congregate to talk about their research and join in. That was science fiction just a few decades ago. The world moves at a fast pace.

Once allotopic expression of the thirteen crucial mitochondrial genes involved in oxidative phosphorylation is realized, undergoing this gene therapy will ensure that the accumulation of mitochondrial DNA damage that occurs over the years no longer contributes to degenerative aging as it does today. It will be an actual, working narrowly focused rejuvenation therapy. As an incidental benefit, this technology will also provide cures for a range of inherited mitochondrial diseases. This work has been underway both at the SENS Research Foundation and in allied labs for some years now, and the biotech company Gensight has been founded on success in allotopic expression of the gene ND4. The SENS Research Foundation in-house team recently achieved success for the mitochondrial genes ATP6 and ATP8, and had a paper accepted by a noted journal, which all in all is a great step forward in a field that has proven to be quite challenging.

Continue reading “Aubrey de Grey and Matthew O’Connor of the SENS Research Foundation Answer Questions on Mitochondrial Research at /r/futurology” »

SRF Summer scholar cited in nature article about the high costs of drug development and how we can reduce them.

In a pioneering move, the compound JQ1 was released to the community for free. The impact that this has had on research and development is slowly coming into focus.